MedTrace Logo

An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia

NCT02077361 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-05-19

No results posted yet for this study

Summary

A project has been developed in Edmonton, Alberta, Canada to enable male patients with choroideremia to access a clinical trial that replaces the defective gene with a normal copy. This experiment is designed to show that the transfer of a normal copy of the gene to the eye is not only safe but may improve the sight of patients. Only Canadian subjects who meet criteria will be recruited.

Conditions

  • Choroideremia

Interventions

GENETIC

rAAV2.REP1 vector

No additional details needed.

Sponsors & Collaborators

  • Alberta Innovates Health Solutions

    collaborator OTHER

  • Canada Foundation for Innovation

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Choroideremia Research Foundation Canada

    collaborator UNKNOWN

  • Foundation Fighting Blindness

    collaborator OTHER

  • Imperial College London

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Ian M MacDonald, MD, CM · University of Alberta

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-08-30
Completion
2022-05-16

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02077361 on ClinicalTrials.gov